ClinicalTrials.gg

Program

SHR-1819

A development code. Also written as “SHR-1819 Injection Blank Preparation”.

In Jiangsu HengRui Medicine's pipeline, IL-4Rα. Its studies are mostly in Dermatitis, Atopic · Asthma, led by Jiangsu HengRui Medicine.

Furthest: phase 3, since May 24, 20245 company-led studies, 1 open or runningNext primary completion: Jun 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jiangsu HengRui Medicine51 open or runningphase 3since May 24, 2024Aug 29, 2020Jun 2027phase 2 · NCT07321951
  • Named in Jiangsu HengRui Medicine’s own pipeline as SHR-1819, phase 3, as of Jul 31, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 29, 2020First study: phase 1 study in Healthy VolunteersFirst studyNCT04561128 · 42 enrolled · Australia
  2. Feb 22, 2021Phase 1 study in AsthmaNCT04772365 · 52 enrolled · China
  3. Sep 19, 2022Phase 2 study in Moderate to Severe Atopic DermatitisNCT05549947 · 158 enrolled · China
  4. May 24, 2024Phase 3 study in Moderate to Severe Atopic DermatitisNCT06468956 · 652 enrolled · China
  5. Dec 21, 2025Phase 2 study in Moderate-to-severe Atopic DermatitisNCT07321951 · 201 enrolled · China

Ahead

  1. Jun 2027Primary completion: phase 2 study in Moderate-to-severe Atopic DermatitisNCT07321951

TargetBeta

“IL-4Rα”the company's pipeline, read by Claude · source

Other programs on IL4R

ProgramCompanyFurthest phaseStudies
dupilumabruleSanofiphase 493
drotokibartJiangsu HengRui Medicinephase 38
TQH2722Sino Biopharmaceuticalphase 37

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07321951Moderate-to-severe Atopic Dermatitis · China2Active, not recruitingJun 2027201
NCT06468956Moderate to Severe Atopic Dermatitis · China3CompletedAug 26, 2026652
NCT05549947Moderate to Severe Atopic Dermatitis · China2CompletedSep 15, 2023158
NCT04772365Asthma · China1CompletedDec 10, 202152
NCT04561128Healthy Volunteers · Australia1CompletedMar 7, 202242

How it is read

Names in the registry

  • “SHR-1819”, 4 entries
  • “SHR-1819 Injection Blank Preparation”, 1 entry

Codes read as this program: SHR1819.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.